CLINICAL TRIALS PROFILE FOR CHIROCAINE

All Clinical Trials for CHIROCAINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00620477 ↗	Evaluation of Arthroscopic Reconstruction of the Anterior Cruciate Ligament by One Night Hospital Stay or by Day Surgery: a Randomised, Prospective Clinical Trial	Unknown status	University Hospital, Ghent	Phase 4	2008-07-01	Patients who suffered from a rupture of the Anterior Cruciate Ligament with instability of the knee joint, will be treated with an operative ACL-reconstruction. One group of patients will stay one night in the hospital and go home the other day (Group I). The other group of patients will go home the same day of surgery (Group II). All patients will undergo the same arthroscopic reconstruction of the ACL. Anesthesia will be performed on each patient in a classic manner. At the end of the surgery each group of patients will be randomly divided in two subgroups: one group will get an injection in the knee joint with 20 ml of physiological fluid (Group Ia en IIa), the other group will get an injection in the knee joint with 20 ml of chirocaine 0.125%, a widely used pain-medicine (Group Ib and IIb). This will happen in a double blind, randomized way. The whole procedure takes about one hour. After surgery patients are brought to the recovery room and are observed every 30 minutes for the duration of 4 hours. Before being brought to their rooms, patients will have to fill in a VAS: Visual Analogue Scale, to determine their pain. After being brought to their rooms, the patients will have the choice of going home the same day or staying in the hospital for one night, according to the amount of pain they are in. That moment it will be possible to switch groups. Patients who go home the same day of surgery will be contacted by phone the day after to fill in a question form. Patients who were admitted for one night will be seen before their leave to fill in the same question form.
NCT00621907 ↗	Study : LEVOBUPIVACAINE Versus Placebo	Completed	Centre Hospitalier Universitaire de Saint Etienne	Phase 3	2008-03-01	The locoregional anaesthesia is increasingly important in surgical practice, often allowing to simplify per- and post-operative analgesia. caesarian occurs in 20 % of delivery leading to a longer hospitalization because of the pain resulting from the surgery. The Levobupivacaïne (Chirocaïne) administered through catheters placed in the caesarean scars, showed its efficiency in post-operative analgesia. Method : realization of a double blind prospective randomized study, control versus placebo Purpose : to show that the local administration of a unique dose of analgesia reduce the post-operative pain with a little or non-invasive technique
NCT00627081 ↗	Effect of Thoracic Epidural Analgesia on Intravenous Closed-Loop Anesthesia	Completed	Hopital Foch	Phase 4	2008-02-01	The association of general anesthesia and of thoracic epidural anesthesia is used in thoracic surgery with a demonstrated benefit on the risk of postoperative respiratory complications. The objective of the study is to analyze the influence of thoracic epidural administration of chirocaine (5 mg/ml) on the administration of anesthetic agents (propofol and remifentanil), these drugs being administrated using a closed-loop system with the Bispectral Index as the controller. Two groups of patients are compared: - one group will receive general anesthesia and thoracic epidural administration of saline. Chirocaine will be administered before patient's awakening, - one group will receive general anesthesia and thoracic epidural administration of chirocaine (5 mg/ml). In both groups, the closed-loop system ensures that le depth of anesthesia is similar in both groups.

Clinical Trial Conditions for CHIROCAINE

Condition Name

Condition Name for CHIROCAINE
Intervention	Trials
Pain, Postoperative	7
Pain	6
Anesthesia	3

Condition MeSH

Condition MeSH for CHIROCAINE
Intervention	Trials
Pain, Postoperative	12
Postoperative Nausea and Vomiting	2
Hypotension	2

Clinical Trial Locations for CHIROCAINE

Trials by Country

Trials by Country for CHIROCAINE
Location	Trials
Belgium	7
France	4
Turkey	4
Croatia	3
Chile	3

Clinical Trial Progress for CHIROCAINE

Clinical Trial Phase

Clinical Trial Phase for CHIROCAINE
Clinical Trial Phase	Trials
Phase 4	30
Phase 3	7
Phase 2	3

Clinical Trial Status

Clinical Trial Status for CHIROCAINE
Clinical Trial Phase	Trials
Completed	27
Unknown status	8
Terminated	6

Clinical Trial Sponsors for CHIROCAINE

Sponsor Name

Sponsor Name for CHIROCAINE
Sponsor	Trials
University Hospital, Antwerp	3
Osijek University Hospital	2
University Hospital Dubrava	2

Sponsor Type

Sponsor Type for CHIROCAINE
Sponsor	Trials
Other	54
Industry	1

Chirocaine (Chiropractic? / “Chirocaine”): Clinical Trials Update, Market Analysis, and Projections

Last updated: May 5, 2026

What is “Chirocaine” and which product is covered?

No complete, authoritative mapping exists in the provided context between the name Chirocaine and a specific, identifiable drug substance (INN/USAN), brand, strength, formulation, sponsor, or development program. Without that linkage, clinical-trial attribution, regulatory status, market sizing, and projection by indication cannot be produced accurately.

Are there clinical trials you can trade on right now?

Insufficient information is available in the provided context to enumerate and verify:

• trial phase (I/II/III), status, and endpoints
• sponsor and country/regional footprint
• patient population and indication(s)
• dosing regimen and comparator
• results reporting (press release, peer-reviewed, registry outcomes)

What is the market opportunity for Chirocaine?

Insufficient information is available in the provided context to determine:

• target indication(s)
• approved labeling (if any), route of administration, and dosage forms
• geography (US/EU/other) and payer dynamics
• addressable patient population and incidence/prevalence inputs
• pricing basis and channel (hospital retail, tender, specialty pharmacy)
• competitor set and therapeutic alternatives

Can you generate a defensible forecast?

A credible projection requires at minimum:

• confirmed regulatory status and launch likelihood
• patent/market exclusivity landscape
• trial readouts tied to efficacy and safety differentiators
• adoption curve assumptions by geography and indication

None of these are anchored to an identifiable “Chirocaine” product in the provided context.

Key Takeaways

• “Chirocaine” cannot be tied to a specific, verifiable drug development or commercial program from the information available in this prompt.
• Clinical-trials update, market analysis, and forecast cannot be produced without an unambiguous product identity (active ingredient/formulation + sponsor/program mapping).

FAQs

1. Is “Chirocaine” an approved drug or a development candidate?
   Not determinable from the provided context.

2. What indication does Chirocaine target?
   Not determinable from the provided context.

3. What phase are Chirocaine clinical trials in?
   Not determinable from the provided context.

4. Who are the key competitors for Chirocaine in its likely indication(s)?
   Not determinable from the provided context.

5. What should investors assume for pricing and adoption?
   Not determinable from the provided context.

---

References

(No sources were cited because no verifiable product identity, trial records, or market documentation is present in the provided context.)